Data-led redesign of plasmid processing: >45% recovery, doubled production capacity and lower costs

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Data-led redesign of plasmid processing: >45% recovery, doubled production capacity and lower costs

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

This webinar presents detailed performance data on how process redesign improves yield, cost-efficiency, and process robustness for both xRNA and viral vector plasmid production. The redesign incorporates redefined lysis and clarification steps, while removing AEX chromatography and tangential flow filtration.

Review quantitative results showing downstream recovery increased from ~30% to over 45% while maintaining high purity and quality standards. Additional data highlights include a 23% reduction in raw material costs, a 19% decrease in full-time equivalent (FTE) hours, and GMP suite time shortened to one week; effectively doubling production capacity.

The session will also provide real-world application data from a client mRNA GMP program, including findings from a 3×3L plasmid process development run and subsequent mRNA production ahead of full GMP validation in early Q1. These results demonstrate readiness for broader industry implementation across both xRNA and viral vector workflows.

Learn how process simplification through the elimination of complex steps like AEX chromatography can streamline downstream purification, reduce variability, and accelerate GMP readiness.

Why attend:

Access quantitative performance data showing >45% recovery yields, −23% raw material costs, and −19% FTE hours
See how a redefined plasmid downstream platform doubles production capacity while maintaining high purity standards
Gain real-world validation insights from application in an active mRNA GMP program
Learn how cross-modality scalability supports both xRNA and viral vector plasmid manufacturing with consistent quality outcomes

Jing Zhu, PhD

VP, Head of Process & Analytical Development at Recipharm Advanced Bio

Dr. Jing Zhu serves as the VP, Head of Process Development at Recipharm Advanced Bio, overseeing process innovations, including advancement of the company’s advanced therapy technology platforms. With extensive experience in process and analytical development, as well as CMC program management, Dr. Zhu has demonstrated exceptional leadership in the pharmaceutical industry. Before joining Recipharm Advanced Bio, Dr. Zhu held various leadership roles across biotech and pharmaceutical companies, including RVAC Medicines and Luye Pharma USA Ltd., focusing on gene therapy applications. His tenure at Thermo Fisher Scientific honed his expertise in purification and analytics, where he held positions ranging from Scientist III to R&D Manager in Bioproduction Purification. Dr. Zhu earned his Ph.D. from the University of California, Davis, specializing in nanofibrous membranes for protein purification, and holds a B.S. in Chemistry from Donghua University. He is also a certified Six Sigma Black Belt, reflecting his commitment to process excellence.

You have registered for this webinar